Telerehabilitation in COVID-19 Survivors

March 13, 2023 updated by: Canan Demir, Bandırma Onyedi Eylül University

Determining the Effectiveness of Telerehabilitation in COVID-19 Survivors

This study was carried out in the post-acute period of the telerehabilitation program in individuals with dyspnea who had COVID-19; It will be done to examine the effects on dyspnea, exercise capacity, respiratory functions, activities of daily living, muscle strength, muscle oxygenation, fatigue and quality of life parameters.

Study Overview

Study Type

Interventional

Enrollment (Actual)

36

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Bandırma
      • Balıkesir, Bandırma, Turkey, 10200
        • Bandırma Onyedi Eylül University, Faculty of Health Sciences, Physiotherapy and Rehabilitation Department

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Diagnosed with COVID-19 by Computed Tomography (CT) or PCR test between the ages of 18-75,
  • Do not have any orthopedic or neurological disease that will affect exercise capacity,
  • Individuals who can take and execute verbal orders,
  • Have had COVID-19 and at least 2 weeks have passed since the completion of the treatment,
  • Individuals who have a computer or smart phone with a camera and internet connection and have the ability to use it (the participant himself or one of his family members living in the same house),
  • Individuals who are sedentary (those whose physical activity level is inactive according to the Turkish version of the International Physical Activity Questionnaire (UFAA)),
  • Having dyspnea at level 2 or 3 on the Medical Research Council Dyspnea Scale.

Exclusion Criteria:

  • Those who have not had COVID-19 or acute period patients who are experiencing COVID-19,
  • Individuals who cannot be contacted,
  • Individuals with chronic heart disease,
  • Those with concomitant uncontrolled disease; uncontrolled hypertension (resting blood pressure ≥160 /100mmHg), uncontrolled diabetes (random instantaneous blood glucose>16.7 mmol/l, HbA1C>7.0%),
  • Those with concomitant severe organic disease (unstable hemodynamic heart disease, heart failure causing movement limitation, unstable angina, MI or other cardiac disease in the last 12 years),
  • Individuals with cerebrovascular disease in the last 6 months,
  • Those with digestive system ulcer, thyroid dysfunction or active stage of tuberculosis,
  • Patients with Chronic Kidney Failure stage 3 and above according to Glomerular Filtration Rate (GFR),
  • Individuals who have undergone intraraticular medication or surgery from their lower extremities in the last 6 months,
  • Individuals who cannot walk independently,
  • Individuals with any mental illness that may prevent them from living independently or receiving treatment,
  • Uncooperative individuals for assessment and rehabilitation programs,
  • Those with alcohol or substance addiction,
  • Those who are pregnant, suspected of pregnancy or considering becoming pregnant,
  • Participants in another study within the last 3 months or currently.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: control group
While other groups continue their exercise program for 6 weeks, this group will only be informed after COVID 19.
will informed after COVID 19
Experimental: home exercise program group
this group will implement COVID 19 home exercise program.
While telerehabilitation sessions will be applied to the participants in the telerehabilitation group for 6 weeks, home exercise program will be given to the home exercise program group and will be applied for 6 weeks.
Experimental: telerehabilitation group
this group will implement COVID 19 telerehabilitation program.
While telerehabilitation sessions will be applied to the participants in the telerehabilitation group for 6 weeks, home exercise program will be given to the home exercise program group and will be applied for 6 weeks.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Severity of dyspnea assessment
Time Frame: 6 weeks
Medical Research Council (MRC) Dyspnea Scale will be used to assess the severity of dyspnea. The severity of dyspnea during activities of daily living is graded from 0 to 4 on the Medical Research Council (MRC) Dyspnea Scale.
6 weeks
Physical activity level assessment
Time Frame: 6 weeks
The physical activity level of the participants will be evaluated with the Turkish version of the "International Physical Activity Questionnaire" (UFAA).In the last 7 days with the survey; Vigorous physical activity (football, basketball, aerobics, cycling fast, lifting weights, carrying loads, etc.) time (min), Intermediate physical activity (light weight carrying, cycling at normal speed, folk dances, dancing, bowling, table tennis etc.) duration (min), walking and sitting times for one day (min) are questioned. All participants were given pre-study to assess the condition of being sedentary and those with inactive physical activity levels will be included in the study.
6 weeks
Cardiopulmonary endurance assessment
Time Frame: 6 weeks
In order to evaluate cardiopulmonary endurance; A six-minute walking test will be applied. The test is 30 meters long, every 3 meters marked, the start and finish line are marked by a visible line, a smooth and straight done on the track. The distance the person walks for 6 minutes is recorded in meters.
6 weeks
Evaluation of peripheral muscle oxygenation
Time Frame: 6 weeks
"Moxy muscle oxygen monitor" will be used to measure regional oxygen saturation (SmO2) and total hemoglobin (Thb) amount in capillaries under the muscle. Moxy muscle oxygen monitor (Fortiori Design LLC, USA) near infrared It is placed on the skin in a non-invasive way with spectroscopy (NIRS), It is a device that regional blood flow and measures oxygenation. A moxy muscle oxygen monitor will be attached to the quadriceps femoris muscle of the participants with a velcro and oxygenation measurements will be taken during both the dinelnim and 6-minute walking test.
6 weeks
Pulmonary function (slow vital capacity)
Time Frame: 6 weeks

Single Breath Count Test will be used to evaluate slow vital capacity (the amount of air exhaled with slow exhalation after deep and maximal inspiration) and lung function. Single breath count (TNS), after maximal effort inhalation an individual with a metronome set to 2 beats per second in a normal speaking voice.

It is a measure of how much you can count in your cadence.

6 weeks
Pulmonary function (Forced vital capacity (FVC))
Time Frame: 6 weeks
Pulmonary function will be evaluated with the spirometry. Dynamic lung volume measurements will be made according to American Thoracic Society and European Respiratory Society criteria. With the device, forced vital capacity (FVC) will be evaluated.
6 weeks
Respiratory Muscle Strength
Time Frame: 6 weeks
Maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) will be measured using portable, electronic, oral pressure measuring device.
6 weeks
Activities of daily living assessment
Time Frame: 6 weeks
Barthel Index will be used to evaluate activities of daily living.
6 weeks
Muscle strength assessment
Time Frame: 6 weeks
Upper and lower extremity muscle strengths will be measured using a manual muscle strength measuring device.
6 weeks
Perceived fatigue assessment
Time Frame: 6 weeks

Participants' perceived fatigue level will be recorded using the "Fatigue Scale". Developed by Borg, modified The category ratio scale (BORG CR-10 SCAL) with 10 degrees in shape is given to certain numbers.

consists of corresponding definitions It will be recorded using the "Fatigue Scale". Developed by Borg, modified The category ratio scale (BORG CR-10 SCAL) with 10 degrees in shape is given to certain numbers consists of corresponding definitions. The Borg Scale is a subjective scale used to evaluate muscle fatigue.

6 weeks
General fatigue assessment
Time Frame: 6 weeks
Participants will be asked to answer the chalder fatigue scale, which includes 11 questions about their fatigue in the past month. The maximum total score is 33; 4 and above scorers are described as tired.
6 weeks
Quality of life assessment
Time Frame: 6 weeks

The Short Form-12 (SF-12) Questionnaire will be used to assess the quality of life.When scoring, two scores are obtained, the physical component and the mental component summary.

is done. High scores indicate good health.

6 weeks
Pulmonary function (Forced expiratory volume in the first second (FEV1))
Time Frame: 6 weeks
Pulmonary function will be evaluated with the spirometry. Dynamic lung volume measurements will be made according to American Thoracic Society and European Respiratory Society criteria. With the device, forced expiratory volume in the first second (FEV1) will be evaluated.
6 weeks
Pulmonary function (FEV1 / FVC)
Time Frame: 6 weeks
Pulmonary function will be evaluated with the spirometry. Dynamic lung volume measurements will be made according to American Thoracic Society and European Respiratory Society criteria. With the device, FEV1 / FVC will be evaluated.
6 weeks
Pulmonary function (Flow rate 25-75% of forced expiratory volume (FEF 25-75%)
Time Frame: 6 weeks
Pulmonary function will be evaluated with the spirometry. Dynamic lung volume measurements will be made according to American Thoracic Society and European Respiratory Society criteria. With the device, flow rate 25-75% of forced expiratory volume (FEF 25-75%) will be evaluated.
6 weeks
Pulmonary function (Peak flow rate (PEF)
Time Frame: 6 weeks
Pulmonary function will be evaluated with the spirometry. Dynamic lung volume measurements will be made according to American Thoracic Society and European Respiratory Society criteria. With the device, peak flow rate (PEF) will be evaluated.
6 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 20, 2021

Primary Completion (Actual)

August 1, 2022

Study Completion (Actual)

August 30, 2022

Study Registration Dates

First Submitted

October 3, 2021

First Submitted That Met QC Criteria

October 8, 2021

First Posted (Actual)

October 12, 2021

Study Record Updates

Last Update Posted (Actual)

March 14, 2023

Last Update Submitted That Met QC Criteria

March 13, 2023

Last Verified

March 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on COVID-19

Clinical Trials on informed program

Subscribe